Terminated PHASE4 INTERVENTIONAL 2-arm NCT01349114

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

Sponsor: Novartis

Conditions Diabetes Hypertension Pre-hypertension

Interventions Placebo/sugar pill aliskiren 300 mg once daily

Updated 8 times since 2017 Last updated: Apr 5, 2017 Started: Jun 30, 2011 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor requested termination.

Other terminated trials from Novartis

See all terminations from Novartis

Other Diabetes trials with similar outcome

Browse all Diabetes trials

Listed as NCT01349114, this PHASE4 trial focuses on Diabetes and Hypertension and remains terminated or withdrawn. Sponsored by Novartis, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE4
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE4
Dec 2021 — Dec 2022 [monthly]

Terminated PHASE4

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
University of Alabama at Birmingham

Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United States